3-Hydroxyl-3-methylglutaryl Coenzyme A (HMG-CoA) Reductase Inhibitor (Statin)-induced 28-kDa Interleukin-1β Interferes with Mature IL-1β Signaling

被引:27
作者
Davaro, Facundo [1 ]
Forde, Sorcha D. [1 ]
Garfield, Mark [2 ]
Jiang, Zhaozhao [1 ]
Halmen, Kristen [1 ]
Tamburro, Nelsy Depaula [1 ]
Kurt-Jones, Evelyn [1 ]
Fitzgerald, Katherine A. [1 ]
Golenbock, Douglas T. [1 ]
Wang, Donghai [1 ]
机构
[1] Univ Massachusetts, Sch Med, Dept Med, Div Infect Dis & Immunol, Worcester, MA 01605 USA
[2] NIAID, NIH, Rockville, MD 20852 USA
基金
美国国家卫生研究院;
关键词
CORONARY EVENTS; IN-VITRO; ATORVASTATIN; RELEASE; STATINS; INFLAMMASOMES; INFLAMMATION; SIMVASTATIN; CASPASE-1; CELLS;
D O I
10.1074/jbc.M114.571505
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Multiple clinical trials have shown that the 3-hydroxyl-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors known as statins have anti-inflammatory effects. However, the underlying molecular mechanism remains unclear. The proinflammatory cytokine interleukin-1 beta (IL-1 beta) is synthesized as a non-active precursor. The 31-kDa pro-IL-1 beta is processed into the 17-kDa active form by caspase-1-activating inflammasomes. Here, we report a novel signaling pathway induced by statins, which leads to processing of pro-IL-1 beta into an intermediate 28-kDa form. This statin-induced IL-1 beta processing is independent of caspase-1-activating inflammasomes. The 28-kDa form of IL-1 beta cannot activate interleukin-1 receptor-1 (IL1R1) to signal inflammatory responses. Instead, it interferes with mature IL-1 beta signaling through IL-1R1 and therefore may dampen inflammatory responses initiated by mature IL-1 beta. These results may provide new clues to explain the anti-inflammatory effects of statins.
引用
收藏
页码:16214 / 16222
页数:9
相关论文
共 45 条
[1]   Effect of atorvastatin with or without prednisolone on Freund's adjuvant induced-arthritis in rats [J].
Abdin, Amany A. ;
Abd El-Halim, Mahmoud S. ;
Hedeya, Sabiha E. ;
El-Saadany, Amira A. E. .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2012, 676 (1-3) :34-40
[2]  
Antonopoulos AS, 2012, CURR PHARM DESIGN, V18, P1519
[3]   Atorvastatin reduces proinflammatory markers in hypercholesterolemic patients [J].
Ascer, E ;
Bertolami, MC ;
Venturinelli, ML ;
Buccheri, V ;
Souza, J ;
Nicolau, JC ;
Ramires, JAF ;
Serrano, CV .
ATHEROSCLEROSIS, 2004, 177 (01) :161-166
[4]   Mechanisms for the anti-inflammatory effects of statins [J].
Bu, De-xiu ;
Griffin, Gabriel ;
Lichtman, Andrew H. .
CURRENT OPINION IN LIPIDOLOGY, 2011, 22 (03) :165-170
[5]   Effects of simvastatin and metformin on inflammation and insulin resistance in individuals with mild metabolic syndrome [J].
Bulcao, Caroline ;
Ribeiro-Filho, Fernando Flexa ;
Sanudo, Adriana ;
Ferreira, Sandra G. Roberta .
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2007, 7 (03) :219-224
[6]  
Dinarello CA, 2002, CLIN EXP RHEUMATOL, V20, pS1
[7]   IL-1: Discoveries, controversies and future directions [J].
Dinarello, Charles A. .
EUROPEAN JOURNAL OF IMMUNOLOGY, 2010, 40 (03) :599-606
[8]   Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels - Results of AFCAPS/TexCAPS [J].
Downs, JR ;
Clearfield, M ;
Weis, S ;
Whitney, E ;
Shapiro, DR ;
Beere, PA ;
Langendorfer, A ;
Stein, EA ;
Kruyer, W ;
Gotto, AM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (20) :1615-1622
[9]   NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals [J].
Duewell, Peter ;
Kono, Hajime ;
Rayner, Katey J. ;
Sirois, Cherilyn M. ;
Vladimer, Gregory ;
Bauernfeind, Franz G. ;
Abela, George S. ;
Franchi, Luigi ;
Nunez, Gabriel ;
Schnurr, Max ;
Espevik, Terje ;
Lien, Egil ;
Fitzgerald, Katherine A. ;
Rock, Kenneth L. ;
Moore, Kathryn J. ;
Wright, Samuel D. ;
Hornung, Veit ;
Latz, Eicke .
NATURE, 2010, 464 (7293) :1357-U7
[10]   REGULATION OF THE MEVALONATE PATHWAY [J].
GOLDSTEIN, JL ;
BROWN, MS .
NATURE, 1990, 343 (6257) :425-430